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Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Improved understanding of the mechanisms
responsible for the differences between IBC and non-IBC might provide novel therapeutic targets. We studied 35 consecutive
patients with IBC, biopsied prior to the initiation of chemotherapy. Angiogenesis was evaluated by Chalkley counting and by
assessment of endothelial cell proliferation (ECP) and vessel maturity. The presence of fibrin, expression of the hypoxia marker
carbonic anhydrase IX (CA IX) and epithelialcadherin (E-cadherin) expression were immunohistochemically detected. The same
parameters were obtained in a group of 104 non-IBC patients. Vascular density, assessed by Chalkley counting (Po0.0001), and ECP
(P¼0.01) were significantly higher in IBC than in non-IBC. Abundant stromal fibrin deposition was observed in 26% of IBC and in
only 8% of non-IBC (P¼0.02). Expression of CA IX was significantly less frequent in IBC than in non-IBC with early metastasis
(P¼0.047). There was a significant positive correlation between the expression of CA IX and ECP in IBC (r¼0.4, P¼0.03), implying
that the angiogenesis is partly hypoxia driven. However, the higher ECP in IBC and the less frequent expression of CA IX in IBC vs
non-IBC points at a role for other factors than hypoxia in stimulating angiogenesis. Strong, homogeneous E-cadherin expression was
found at cell–cell contacts in all but two IBC cases, both in lymphovascular tumour emboli and in infiltrating tumour cells, challenging
our current understanding of the metastatic process. Both the intense angiogenesis and the strong E-cadherin expression may
contribute to the highly metastatic phenotype of IBC.
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Inflammatory breast cancer (IBC) constitutes less than 10% of all
breast cancers (Chevallier et al, 1987; Fields et al, 1989; Alpaugh
et al, 1999). It is a distinct and most aggressive form of locally
advanced malignant breast disease. Although multimodality
treatments have achieved significant improvements in both
disease-free and overall survival (Chambler et al, 1995), prognosis
is still extremely poor because of the high incidence of local
recurrence and systemic metastases. Very little is known about the
pathogenesis of IBC. Only few studies have examined the
differences between IBC and non-IBC (Aziz et al, 2001). However,
a better understanding of the effector molecules responsible for the
IBC phenotype might provide important new therapeutic targets.
Recently, using a semiquantitative reverse transcriptase poly-
merase chain reaction, Shirakawa et al (2002b) showed that
angiogenic, but not lymphangiogenic factors are overexpressed in
resected specimens of 19 IBC patients when compared with 23
non-IBC tumours. In the same study, a significantly higher
population of tumour-infiltrating endothelial cells or endothelial
precursor cells was immunohistochemically found in the tumour-
associated stroma of IBC specimens than in non-IBC specimens.
The authors conclude that IBC tumours induce angiogenesis and
vasculogenesis that involves recruitment of endothelial cells or
endothelial precursor cells. They further studied the pathways
involved in IBC angiogenesis in an IBC xenograft model (WIBC-9)
originating from a patient with IBC. Histologically, WIBC-9
xenografts exhibited invasive ductal carcinoma with angiogenesis
at the tumour margin and vasculogenic mimicry with absence of
endothelial cells in addition to necrosis and fibrosis in the tumour
centre (Shirakawa et al, 2002a). To the best of our knowledge,
however, quantitative morphologic studies of angiogenesis in
human IBC have not yet been performed.
Another well-studied xenograft model of IBC is the human-
severe combined immunodeficient/nude mice model MARY-X
(Alpaugh et al, 1999; Tomlinson et al, 2001, Alpaugh et al, 2002).
Comparative studies of MARY-X with non-IBC xenografts
indicated a 10–20-fold overexpression of E-cadherin. Cadherins
are a family of transmembranous glycoproteins responsible for
calcium-dependent, homophilic intercellular adhesion (Takeichi,
1991). Epithelial cadherin (E-cadherin) is present in most normal
adult epithelial tissues and plays a critical role in the maintenance
of normal tissue architecture. Tomlinson et al (2001) studied 25
cases of human IBC and found E-cadherin membrane immuno-
reactivity in all cases. Kleer et al (2001) found strong expression of
E-cadherin in 100% of 20 human IBC tumours and in only 68% of
22 stage-matched non-IBC tumours. IBC therefore constitutes an
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yimportant exception to the association between loss of E-cadherin
expression and increased metastatic potential and poor outcome in
breast cancer. Indeed, the E-cadherin-mediated cell adhesion
system is known to act as an invasion suppressor system in cancer
cells (Vleminckx et al, 1991) and diminished E-cadherin expres-
sion has been related to invasiveness, dedifferentiation, lympho-
vascular invasion, lymph node metastasis, distant metastasis and
shortened disease-free survival (Oka et al, 1993; Jones et al, 1996;
Siitonen et al, 1996; Asgeirsson et al, 2000; Heimann et al, 2000).
The strong E-cadherin expression in IBC, being a highly invasive,
poorly differentiated tumour with prominent lymphovascular
invasion and high incidence of lymph node and distant metastasis,
therefore constitutes a striking difference between IBC and non-
IBC.
The aim of this study was to provide quantitative morphologic
data on angiogenesis in human IBC and to confirm the aberrant
E-cadherin expression in a group of 35 IBC patients.
PATIENTS AND METHODS
Patients
We studied 35 consecutive patients with newly diagnosed primary
IBC of whom sufficient formalin-fixed, paraffin-embedded tissue
was available, biopsied prior to the initiation of chemotherapy.
Mean patient age was 55.6 years (range: 25–83 years). All patients
showed diffuse enlargement of the involved breast of sudden onset
(all less than 8 weeks, median 5 weeks). There was erythema and
oedema of the skin involving more than one-third of the breast. In
some patients, a poorly circumscribed tumour was palpable. There
was no tumour fungation or skin ulceration. The material
consisted of 32 large incisional breast biopsies with overlying skin
and of three trucut biopsies. Dermal lymphovascular permeation
was found at the time of initial diagnosis in 23 patients (66%),
which is consistent with literature data (Bonnier et al, 1995). In
three additional patients, dermal lymphatic tumour emboli were
found at the time of mastectomy, yielding a pathological
confirmation of the clinical diagnosis in 74% of the cases.
Parenchymal lymphatic invasion was commonly seen.
The haematoxylin–eosin stained slides were reviewed to select
the paraffin block best suitable for additional immunohistochem-
ical stains. All selected blocks contained both infiltrative
carcinoma and lymphovascular tumour emboli, dermal or paren-
chymal, except for one trucut biopsy in which lymphovascular
permeation was not present.
Microvessel density (Chalkley count)
Rehydrated paraffin sections were immunostained with a mono-
clonal antibody against CD34 (clone QBEnd/10, Biogenex, San
Ramon, USA) diluted 1:5 with overnight incubation at 41C and
without any antigen retrieval procedure. A biotinylated secondary
antibody, avidin–peroxidase as an enzyme and diaminobenzidine
tetrahydrochloride (DAB) as a chromogenic substrate were used to
visualise binding of the first antibody. Microvessel density was
determined with the Chalkley method (Chalkley, 1943). This is a
morphometric point counting system using a microscope eyepiece
graticule and has been suggested as a standard in international
consensus reports on quantification of angiogenesis (Vermeulen
et al, 1996, 2002). The areas of highest vascular density (‘hot
spots’) were identified at low magnification ( 10 ocular and  10
objective). On a higher magnification ( 10 ocular and  20
objective, Chalkley grid area 0.22mm
2), a 25-point Chalkley
eyepiece graticule was applied to each hot spot and oriented to
permit the maximum number of points to hit on or in an
immunostained microvessel. Chalkley counting was performed in
a mean number of seven (range 3–13) hot spots per slide. The
Chalkley count was expressed as ‘Chalkley max’, the count in the
hot spot with highest vascular density and ‘Chalkley mean’, the
mean of the three highest counts.
Endothelial cell proliferation
For the quantification of proliferating endothelial cells, a
proliferating cell nuclear antigen (PCNA)-CD34 double-labelling
immunohistochemical staining was performed. A monoclonal
antibody directed against PCNA (PC10, Medac, Wedel, Germany;
prediluted) was applied to the rehydrated paraffin sections and
allowed to incubate overnight at room temperature. A secondary
antibody linked to peroxidase and DAB were used to visualise
binding of the first antibody. The sections were then incubated
overnight at 41C with an antibody against CD34 (clone QBEnd/10,
Biogenex, San Ramon, CA, USA) diluted 1:5. The staining was
completed with the Ventana Basic Alkaline Phosphatase Red
detection kit (Ventana Medical Systems, Inc., Strasbourg, France)
on the Ventana NexES automated immunostainer.
The fraction of proliferating endothelial cells (ECP%) was
assessed in the areas of highest vascular density (‘hot spots’),
identified at low magnification ( 10 ocular and  10 objective).
On a higher magnification ( 10 ocular and  40 objective), a
total number of 100 endothelial cells were evaluated per hot spot
and ECP% was the number of endothelial cells with PCNA-stained
nuclei per 100 endothelial cells. ECP% max is the fraction of
proliferating endothelial cells in the hot spot with the highest
endothelial cell proliferation and ECP% mean is the mean of the
three highest fractions.
Blood vessel maturation and microvessel density
(Weidner method)
For the assessment of blood vessel maturation, another double-
labelling immunohistochemical technique was used to simulta-
neously stain endothelial cells (CD34) and mural cells (a-smooth
muscle actin). Paraffin sections were incubated with an antibody to
CD34 (clone QBEnd/10, Biogenex, San Ramon, CA, USA; 1:5
dilution; overnight incubation) without prior antigen retrieval. A
secondary antibody linked to peroxidase followed by DAB was
used to visualise the CD34 antigen. The slides were then placed on
the Ventana NexES automated immunostainer and stained with an
antibody against a-smooth muscle actin (clone 1A4, Biogenex, San
Ramon, CA, USA; 1:80 dilution, 32min) and the Ventana Basic
Alkaline Phosphatase Red detection kit (Ventana Medical Systems,
Inc.). Blood vessel immaturity was again assessed in the vascular
hot spots, identified at low magnification ( 10 ocular and  10
objective). On a higher magnification ( 10 ocular and  25
objective; microscopic field area 0.42mm
2), the percentage of
immature vessels was calculated as the number of CD34-labelled
blood vessels not associated with a-smooth muscle actin positive
mural cells (pericytes and smooth muscle cells)/total number of
blood vessels in the microscopic field.
This total number of vessels also provided us with a
quantification of microvessel density according to the method
described by Weidner et al (1991).
Fibrin
The presence of fibrin was detected immunohistochemically with
the NYB.T2G1 monoclonal antibody (Accurate Chemical and
Scientific Corporation, Westbury, NY, USA), which reacts with the
amino-terminal part of the Bb chain only after removal of
fibrinopeptide B by thrombin, and hence binds to fibrin but not
fibrinogen. The staining was performed on the Ventana NexES
automated immunostainer. After protease digestion for 6min
(Sigma p4789 type XXVVII, Sigma-Aldrich, Bornem, Belgium), the
primary antibody was incubated for 32min at a dilution 1:100.
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antibody linked to peroxidase and with DAB, as described above.
The presence of fibrin was scored semiquantitatively (abundant:
fibrin easily seen at low magnification ( 40), sparse: small
deposits of fibrin only visible at higher magnification (4 100),
absent: no fibrin).
Carbonic anhydrase IX (CA IX)
Immunohistochemical staining for the endogenous hypoxia
marker CA IX was performed at the Weatherall Institute of
Molecular Medicine in Oxford with the murine monoclonal
antibody M75 at a dilution of 1:50. The ability of this antibody
to specifically detect CA IX expression in tissue sections was
previously confirmed by direct correlation with Western blot
analysis in human breast tumour specimens (Wykoff et al, 2001).
After an incubation time of 60min at room temperature, a
peroxidase conjugated to goat anti-mouse immunoglobulins (Dako
Envision+System, peroxidase, mouse; Dako, Glostrup, Denmark)
was allowed to incubate for 30min. Slides were then stained with
DAB and counterstained with haematoxylin. The immunostaining
was quantified both in the infiltrative tumour and in the
lymphovascular tumour emboli, by semiquantitative scoring as
previously described (Chia et al, 2001). In brief, a score of 0–3 for
the intensity of staining was given (0: no staining, 1: weak staining,
2: moderate staining, 3: strong staining). The percentage of
immunostained tumour cells was estimated. The product
(intensity score the percentage of immunoreactive tumour cells)
yielded a final score of 0–300. For statistical evaluation, any
percentage of immunostaining was called positive.
E-cadherin
Immunohistochemical staining for E-cadherin was performed with
the murine monoclonal antibody HECD-1 (Human Epithelial
Cadherin-1, Takara, Kyoto, Japan). Rehydrated paraffin sections
were pretreated for 30min in an EDTA-buffer (pH 9; DAKO PP20-
0226) at 961C. The primary antibody was incubated for 60min at a
concentration of 1.3mgml
 1. The staining was completed with a
biotinylated secondary antibody, avidin–peroxidase and DAB.
E-cadherin expression was assessed semiquantitatively. The
percentage of tumour cells showing E-cadherin expression at
cell-cell contacts was estimated and the intensity of staining was
compared with the staining of normal epithelia such as the
epidermis and normal mammary ducts (1: weaker than normal
structures, 2: staining intensity similar to normal structures, 3:
stronger than normal structures). The product (intensity scor-
e the percentage of immunoreactive tumour cells) yielded a final
score ranging from 0 to 300. A separate score was given for the
infiltrative tumour and the lymphovascular tumour emboli.
Noninflammatory breast cancer patients (non-IBC)
For comparison, the same parameters were assessed in a group of
104 non-IBC patients, which we studied before (Colpaert et al,
2001a). This group consisted of lymph node-negative breast cancer
patients, with an unfavourable subgroup of 46 consecutive patients
who developed early distant relapse after a median disease-free
survival of 25 months, and a favourable subgroup of 58 patients
who were still disease-free after a median follow-up of 91.5
months. The rapid clinical progression of the non-IBC patient
group with early distant metastasis makes it a relevant control
group for the IBC patients from a clinical point of view.
None of the non-IBC patients received systemic adjuvant
therapy. Mean age at diagnosis was 53710.7 years for the
unfavourable subgroup and 55.9710.4 years for the favourable
subgroup. Tumour size was 2.0270.79cm in the former and
1.6970.83cm in the latter group. A total of 42% of the tumours
with unfavourable outcome and only 14% of the tumours with
favourable outcome were of high histological grade.
Most parameters were assessed on the total patient group. For
endothelial cell proliferation and vessel maturation, 16 patients
from the unfavourable group and 18 patients from the favourable
group were randomly selected.
Statistics
Results were analysed for statistical significance by the Mann–
Whitney U-test or the Kruskal–Wallis test for continuous
variables in different subgroups. The w
2-square test was used for
testing relations between categorical variables and correlation
analysis was used for continuous variables. A P-value o0.05 was
required for significance. Statistical calculations were performed
with the Statview 4.51 program (Abacus Concepts; Apple
Macintosh).
RESULTS
Microscopical phenotype
The microscopical phenotype was evaluated on the haematoxylin–
eosin stained slides. All IBC had a diffusely infiltrative growth
pattern. There was no well-circumscribed tumour. Instead, the
carcinoma infiltrated between pre-existing structures such as
mammary lobules and ducts, often with the formation of multiple
small expansive tumour nodules, consisting of carcinoma and
desmoplastic tissue. All IBC were of high histological grade:
tubular formation was seen in only one case, nuclear pleomorph-
ism was considerable and there was brisk mitotic activity.
Necrosis was not a prominent feature in IBC. Only seven cases
showed small foci of necrosis in the expansive nodules of
infiltrative carcinoma. Remarkably, necrosis was seen in the
lymphovascular tumour emboli of eight patients. None of the IBC
cases contained a fibrotic focus that is, a scar-like area replacing
necrosis (Colpaert et al, 2001b).
Angiogenesis-related parameters
All parameters related to angiogenesis are summarised in Table 1.
Microvessel density, quantified by the Chalkley method, was
significantly higher in IBC than in non-IBC (Po0.0001). Since the
Chalkley method is an estimate of relative area, this means that the
intratumoural vascular area was significantly larger. The vessels
were often tortuous, branched and dilated, and vascular permea-
tion of tumour cells was frequent (Figure 1). The intravascular
tumour emboli were never covered by endothelium.
Microvessel density (MVD), quantified by the Weidner method
(Weidner et al, 1991), is a measurement of the number of
microvessels in a microscopic field. This number was not
significantly different in IBC and non-IBC: mean MVD
68.6728.9 (median 61.2) in IBC and 72.9721.9 (median 73.5) in
non-IBC.
Although the mean percentage of immature vessels, that is,
vessels consisting of endothelial cells not supported by mural cells
(Figure 2), was as high as 87.3%, this was not significantly different
from non-IBC.
The fraction of proliferating endothelial cells (ECP%; Figure 3)
was significantly higher in IBC than in non-IBC: mean ECP% was
19% in IBC vs 11% in non-IBC (P¼0.014). There was no
correlation between mean ECP% and microvessel density (both
Chalkley and Weidner method), mean percentage of immature
vessels or stromal fibrin deposition.
The endogenous hypoxia marker CA IX was expressed in only
46% of the IBC patients, while it was expressed in 68% of non-IBC
patients with unfavourable prognosis (P¼0.047) and in 45% of
non-IBC patients with favourable prognosis. When present, CA IX
Angiogenesis and E-cadherin in inflammatory breast cancer
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cells, although in nine patients, immunoreactivity for this hypoxia
marker was also seen in intravascular tumour emboli (Figure 4).
Only three of these patients also showed necrosis in the tumour
emboli.
There was a significant positive correlation between the
expression of CA IX and mean ECP in IBC (r¼0.4, P¼0.03,
95% CI¼0.04–0.7). Mean ECP% was 27.3715.5 (26.3) when CA
IX expression was present vs 14.8711.2 (12.8) when CA IX was not
expressed (P¼0.04). Similarly, the maximal ECP% was 32.3718.4
(27.5) when CA IX was present vs 18.9713.9 (17.5) when CA IX
was absent (P¼0.04).
Stromal fibrin depositions were found in 57% of IBC patients.
These depositions were abundant in 26% of IBC patients (Figure 5)
and in only 8% of non-IBC patients (P¼0.03).
E-cadherin
Expression of the epithelial cell–cell adhesion molecule E-cadherin
was observed in all but two of the IBC patients. The immunostain-
ing was strikingly homogeneous, all tumour cells showing
membranous immunoreactivity at cell–cell contacts (Figure 6).
In most patients, the staining intensity was equally strong in the
infiltrating carcinoma cells as in the lymphovascular tumour
emboli; the latter stained more intensely than the former in five
cases. The staining intensity of both infiltrative carcinoma and
lymphovascular tumour emboli was usually similar to that of
normal epithelial structures such as the epidermis or normal
mammary ducts. In five patients, expression of E-cadherin was
weaker in the tumour cells than in the normal structures, but in six
cases the opposite was true. No correlation was found between the
intensity of E-cadherin immunostaining and the expression of the
hypoxia marker CA IX.
Both carcinomas totally lacking E-cadherin expression showed a
scattered growth pattern as in infiltrating lobular carcinomas, but
with more pleomorphic nuclei. There was immunoreactivity at the
intercellular junctions of the epidermis, serving as a positive
internal control. Both patients showed the typical clinical features
Table 1 Angiogenesis-related parameters in inflammatory breast cancer (IBC)
Parameter IBC n=35
Non-IBC
unfavourable
Non-IBC
favourable
P-value
(IBC vs non-IBC/*global)
Mean Chalkley count 11.674.1 (11.0) 8.672.2 (8.6) 7.272.1 (7.2) o0.0001
n=46 n=56 *o0.0001
Maximal Chalkley count 13.074.3 (12.0) 9.672.6 (10) 8.072.4 (8.0) o0.0001
n=46 n=56 *o0.0001
Mean % immature vessels 87.3712.6 (92.3) 88.3710.2 (91.0) 84.0713.7 (90.0) >0.1
n=16 n=18 *>0.1
Maximal % immature vessels 93.278.9 (97.0) 94.177.4 (97.5) 90.4711.3 (93.0) >0.1
n=16 n=18 *>0.1
Mean ECP% 19.2714.4 (15.3) 10.975.4 (8.6) 11.178.1 (9.0) 0.014
n=16 n=17 *0.049
Maximal ECP% 23.6717.1 (20.0) 14.576.5 (11.5) 14.5710.5 (12.0) 0.04
n=16 n=17 *0.11
CA IX expression Present: 16 Present: 28 Present: 24 >0.1
Absent: 19 Absent: 13 Absent: 29 *0.046
Stromal fibrin deposition None: 15 None: 21 None: 25 0.02
Sparse: 11 Sparse: 22 Sparse: 26 *0.08
Abundant: 9 Abundant: 3 Abundant: 5
ECP%=fraction of proliferating endothelial cells; CA IX=carbonic anhydrase IX. Continuous variables are represented as mean7s.d. (median).
Figure 1 Highly vascularised area in IBC, showing tortuous and dilated
vessels and vascular permeation (arrow) of tumour cells (CD 34
immunohistochemical stain). Scale bar¼40mm.
Figure 2 Mature vessels (thick arrows) lined by endothelial (brown) and
mural cells (red) and immature vessels lined by endothelium only (thin
arrows) and containing tumour emboli (CD34-a-smooth muscle actin
immunohistochemical doublestain). Scale bar¼30mm.
Angiogenesis and E-cadherin in inflammatory breast cancer
CG Colpaert et al
721
British Journal of Cancer (2003) 88(5), 718–725 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yof inflammatory breast cancer and the diagnosis was confirmed
with a skin biopsy showing dermal lymphovascular tumour
emboli.
DISCUSSION
Most of our limited knowledge about the molecular mechanisms or
pathogenesis of IBC has been obtained in human IBC xenograft
models. In the present study, we verified some of the findings in
these models in actual cases of human IBC.
A well-studied model for IBC is the human-severe combined
immunodeficient/nude mice transplantable xenograft MARY-X
(Alpaugh et al, 1999, 2002; Tomlinson et al, 2001). MARY-X
consists of a confluence of tumour nodules growing in a host
mesenchyme in the central part of the xenograft and tumour
emboli within lymphovascular spaces at the tumour’s periphery.
Western blot analysis of MARY-X compared with non-IBC
xenografts revealed a 10–20-fold overexpression of E-cadherin
and MUC1, but markedly decreased sialyl-Lewis X/A carbohydrate
ligand-binding epitopes. The latter are necessary for binding
endothelial cell E-selectin, and their deficiency results in a tumour
cell–endothelial cell aversion. The strong homotypic tumour cell–
tumour cell adhesion mediated by the epithelial cell–cell adhesion
molecule E-cadherin, together with the weak heterotypic tumour
cell–endothelial cell adhesion, generates metastases in the form of
compact spheroids. This phenomenon would explain the efficiency
of metastatic dissemination in IBC. It has been known for several
decades that haematogenous multicellular tumour cell clusters are
more efficient at forming metastases than single cells (Liotta et al,
1976). Furthermore, tumour cell clumps are hypoxic in their
centres and therefore resistant to the effects of radiation therapy
and chemotherapy (Moore et al, 1992).
In the present study of 35 human IBC cases, lymphovascular
tumour emboli were seen in all but one patient. Expression of the
hypoxia marker CA IX and necrosis of the tumour emboli were
Figure 3 Immunohistochemical doublestain to demonstrate proliferating
(brown nucleus) and nonproliferating (blue nucleus) endothelial cells
(PCNA-CD34 immunohistochemical doublestain). Scale bar¼18mm.
Figure 4 Intravascular tumour embolus, with hypoxic cells in the centre
showing membranous immunoreactivity for the hypoxia marker carbonic
anhydrase IX (CA IX immunohistochemical stain). Scale bar¼70mm.
Figure 5 Abundant fibrin deposition in the stroma surrounding a vessel
(T2G1 immunohistochemical stain). Scale bar¼36mm.
Figure 6 E-cadherin expression in infiltrating carcinoma cells (thin
arrow), in the lymphovascular tumour emboli (thick arrow) and in a normal
mammary duct (asterisk). All tumour cells show homogeneous membra-
nous immunoreactivity at cell–cell contacts. (E-cadherin immunohisto-
chemical stain). Scale bar¼60mm.
Angiogenesis and E-cadherin in inflammatory breast cancer
CG Colpaert et al
722
British Journal of Cancer (2003) 88(5), 718–725 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
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patients showing both lymphovascular CA IX expression and
necrosis. Strong E-cadherin expression was seen at the cell–cell
contacts of all tumour cells in 94% of the patients. This confirms
the experimental observations in MARY-X and the overexpression
of E-cadherin described earlier in a limited number of human IBC
cases. In our study, the immunoreactivity for E-cadherin in the
lymphovascular tumour emboli was equally strong or even
stronger–and never weaker–than in the infiltrative carcinoma
cells. Nevertheless, the latter also showed homogeneous E-cadherin
expression at cell–cell contacts in all tumour cells. It is difficult to
understand how these cohesive tumour cells, strongly expressing
the invasion-suppressor molecule E-cadherin (Vleminckx et al,
1991), can establish their highly invasive phenotype with florid
lymphovascular invasion. Indeed, the current dogma is that the
metastatic process requires decreased tumour cell–tumour cell
adhesion, active invasion of the extracellular matrix, intravasation,
extravasation and secondary growth at the metastatic site
(Weidner, 2002). It has been suggested, however, that IBC bypasses
some of the classic steps of metastatic progression (Alpaugh et al,
2002). Preliminary studies would indicate that the tumour cell
embolus in IBC finds itself within the vascular lumen because it
stimulates a vascular channel to form around it rather than
intravasating into pre-existing lymphatics or capillaries. This
mechanism shows some similarities with an invasion-independent
pathway of blood-borne metastasis described earlier in a murine
mammary tumour model (Sugino et al, 2002). In that model, the
tumour nests gain access into blood vessels not through active
intravasation, but because they are enveloped by vascular
endothelial cells. The tumour embolus conserves its tissue
organisation and endothelial covering and is mechanically arrested
in a pulmonary arteriole where it proliferates intravascularly. Both
in the MARY-X xenograft model of IBC and in the human IBC
cases described in the present study, the intravascular tumour
emboli conserve tissue organisation by maintaining a nested
architecture and strong intercellular adhesion, but were never
covered by endothelium. This constitutes a major difference with
the invasion-independent murine mammary tumour model
described above. Other recent studies have challenged the
canonical steps of the metastatic process and found that
haematogenous metastases originate from the proliferation of
attached intravascular tumour cells rather than from extravasated
ones (Al-Mehdi et al, 2000). Interestingly, pulmonary emboli of the
MARY-X xenograft model do not extravasate either (Alpaugh et al,
1999).
Prerequisites for the formation of a vascular channel enveloping
tumour cell nodules, as described in the invasion-independent
pathway of metastasis, are high angiogenic activity and sinusoidal
remodelling of tumour blood vessels (Sugino et al, 2002). We
present strong evidence that there is indeed intense ongoing
angiogenesis in human IBC. This is manifested by high Chalkley
counts and high endothelial cell proliferation fractions. High
Chalkley counts reflect high intratumoural vascular area. Indeed,
the vessels in IBC were often tortuous, branched and dilated,
thereby providing a large contact area between tumour cells and
endothelial cells. This may be important for the paracrine
interactions between these cells (Folkman, 1994) and may also
mechanically promote the metastatic process by facilitating the
entry of tumour cells into the vascular lumina. Newly formed
proliferating capillaries often have fragmented basement mem-
branes and are leaky, making them more accessible to tumour cells
than mature vessels (Weidner, 2002). We showed that the mean
percentage of immature vessels, defined as vessels lined by
endothelial cells unsupported by mural cells, was almost 90% in
the most vascularised areas of human IBC.
Despite the significantly higher Chalkley counts, microvessel
density quantified by the Weidner method was not significantly
higher in the IBC patients than in the non-IBC patients used for
comparison. This means that the number of vessels counted in the
most vascularised areas was not significantly higher. The number
of vessels in a microsopic field is the result of angiogenesis, vessel
remodelling and angioregression. If the latter predominates over
the former, even highly angiogenic tumours can have low MVDs.
Sinusoidal remodelling of vessels, as described in the invasion-
independent murine mammary tumour model (Sugino et al, 2002),
results in high intratumoural vascular area with high Chalkley
counts, but low MVD according to Weidner.
The high fraction of proliferating endothelial cells (ECP) is the
strongest argument for intense ongoing angiogenesis in the cases
of human IBC presented in this study. There was a significant
positive correlation between the expression of the hypoxia marker
CA IX and ECP, implying that the angiogenesis is at least partly
hypoxia driven. CA IX is one of the cell surface transmembrane
carbonic anhydrases involved in maintaining an acidic extra-
cellular pH in tumours. Its transcription is regulated by hypoxia
inducible factor-1 (HIF-1), an important mediator of gene
expression patterns in response to hypoxia in tumours (Wykoff
et al, 2000). Other genes upregulated by hypoxia through
activation of HIF-1 are angiogenic growth factors including VEGF
(Forsythe et al, 1996; Jiang et al, 1997; Maxwell et al, 1997). This is
a major molecular pathway for hypoxia-driven angiogenesis.
The expression of CA IX was significantly less frequent in IBC
than in non-IBC, especially when compared to non-IBC patients
with unfavourable prognosis. This suggests that intratumoural
hypoxia is not a prominent feature of IBC and is supported by the
fact that necrosis was present only focally in a minority of cases
and that none of the IBC cases contained a fibrotic focus (Colpaert
et al, 2001b). The presence of necrosis and CA IX expression in
intravascular tumour emboli (Figure 4) is of interest, indicating the
potentially unfavourable hypoxic microenvironment of these
channels. Thus, there may be further selection for aggressive
cancer cells surviving this route. The intravascular hypoxia may be
because of acute intermittent vessel shut down, that is, acute
hypoxia, now thought to be an important contributor to radiation
and drug resistance (Harris, 2002).
The less frequent presence of CA IX in IBC vs non-IBC contrasts
with the significantly higher ECP in IBC and points at a role for
still other factors than hypoxia in stimulating angiogenesis. A
possibly important oncogene product in that context is RhoC
GTPase (Van Golen et al, 2000a, b), which was found to be
overexpressed in 90% of archival IBC tumour samples, but not in
stage-matched non-IBC tumours. High levels of VEGF, basic
fibroblast growth factor, interleukin-6 and interleukin-8 were
found in the conditioned media of transfectants of human
mammary epithelial cells overexpressing the RhoC gene. More-
over, these transfectants were more motile with an increase in actin
stress fibres and focal adhesion contact formation. These data
suggest that overexpression of RhoC GTPase is a specific genetic
alteration of IBC leading to the highly invasive phenotype of IBC
and to the production of angiogenic factors irrespective of
intratumoural hypoxia.
Indirect evidence for high VEGF production in IBC is the
abundant stromal fibrin deposition observed in 26% of IBC and in
only 8% of non-IBC cases. VEGF is also known as vascular
permeability factor (VPF) and promotes extravasation of plasma
fibrinogen, leading to fibrin deposition in the tumour matrix,
which promotes the ingrowth of macrophages, fibroblasts and
endothelial cells (Dvorak et al, 1995).
In conclusion, we showed that strong E-cadherin expression and
intense ongoing angiogenesis are present in human IBC. Both
features may contribute to the high metastatic efficiency of IBC.
Furthermore, the intense ongoing angiogenesis demonstrates that
IBC patients are a homogeneous population suffering from an
angiogenesis-dependent form of breast cancer with poor prog-
nosis. This leads to a clinically recognisable, well-defined target
population for the implementation of new treatment strategies
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anti-VEGF) compounds.
Further molecular studies comparing IBC and non-IBC are
needed in order to identify transcriptional and transla-
tional pathways responsible for the inflammatory carcinoma
phenotype.
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